Cardiff Oncology Inc (CRDF) Stock Price, Quote & News

Company Profile

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative brea...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 952 7570

Website: www.cardiffoncology.com

Address:

11055 Flintkote Avenue, San Diego, United States

Swing22 Aug. 24 at 3:17 PM

$CRDF great time to sell this loser stock and move on with your life

0 · Reply

spaarrow1 Aug. 24 at 3:16 PM

$CRDF Im waiting for BO. But Will not happend.

0 · Reply

Blakeruss1 Aug. 24 at 3:13 PM

$CRDF meteoric rise this morning!! Flat rest of day until buyout announced later

0 · Reply

spaarrow1 Aug. 24 at 3:10 PM

$CRDF This a pump and dump. Tomorrow 0.9

0 · Reply

jrh34 Aug. 24 at 2:56 PM

$CRDF Sure seems like a settlement has been reached - and leaked by the lawyers. So now let's talk about what type of valuation that could put on $CRDF if the details become public later today or tomorrow? I think a swift move to $2.50-3 range is likely. And it trades there until we get details around funding a P3, update on mPFS for 30mg cohort, or partnership news. What do others think?

1 · Reply

Blakeruss1 Aug. 24 at 2:45 PM

$CRDF I heard buyout between 55-60

2 · Reply

DBOCK Aug. 24 at 2:43 PM

$CRDF Please announce a settlement so we can move forward with this behind us.

0 · Reply

JanetBSmellin Aug. 24 at 2:31 PM

$CRDF Buyout $5.00😛

2 · Reply

jrh34 Aug. 24 at 2:30 PM

$CRDF So true, if you think this move is likely related to insiders knowing the result, then there's a lot more room to run once a settlement becomes public. Volume here would certainly suggest some subset of people know news is coming.

0 · Reply

OneSmartBull Aug. 24 at 2:26 PM

$CRDF

0 · Reply

Cardiff Oncology reports Q2 EPS (14c), consensus (16c)

2026-08-17T11:06:12.000Z - 7 days ago

Cardiff Oncology downgraded to Market Perform from Outperform at William Blair

Aug 14, 2026, 8:00 AM EDT - 10 days ago

Cardiff Oncology Proxy statement: Proxy filing

Aug 11, 2026, 4:10 PM EDT - 12 days ago

Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update

Aug 11, 2026, 7:00 AM EDT - 13 days ago

Cardiff Oncology Quarterly report: Q2 2026

Aug 11, 2026, 7:00 AM EDT - 13 days ago

Cardiff Oncology Earnings release: Q2 2026

2026-07-15T12:15:16.000Z - 5 weeks ago

Cardiff Oncology announces $10M registered direct offering

Jul 15, 2026, 8:00 AM EDT - 5 weeks ago

Cardiff Oncology Announces $10 Million Registered Direct Offering

2026-06-05T11:13:07.000Z - 2 months ago

Cardiff Oncology price target lowered to $4 from $10 at Lucid Capital

Jun 4, 2026, 10:30 AM EDT - 2 months ago

Cardiff Oncology Transcript: Jefferies Global Healthcare Conference 2026

2026-06-03T16:55:09.000Z - 2 months ago

Craig-Hallum downgrades Cardiff Oncology to Hold, lowers target to $2

2026-06-03T16:07:35.000Z - 2 months ago

Cardiff Oncology downgraded to Hold from Buy at Craig-Hallum

Jun 3, 2026, 8:30 AM EDT - 2 months ago

Cardiff Oncology Transcript: Status update

Jun 3, 2026, 8:30 AM EDT - 2 months ago

Cardiff Oncology Press release: Status update

Jun 3, 2026, 8:30 AM EDT - 2 months ago

Cardiff Oncology Slides: Status update

2026-06-02T14:11:15.000Z - 2 months ago

Cardiff Oncology announces results from CRDF-004 trial

Jun 2, 2026, 9:06 AM EDT - 2 months ago

Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting

Jun 1, 2026, 4:01 PM EDT - 2 months ago

Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference

2026-06-01T10:28:20.000Z - 3 months ago

Cardiff Oncology downgraded to Neutral from Buy at H.C. Wainwright

2026-06-01T10:26:56.000Z - 3 months ago

Cardiff Oncology says NMS terminating license agreement

2026-06-01T10:26:21.000Z - 3 months ago

Cardiff Oncology downgraded to Hold from Buy at TD Cowen

May 21, 2026, 5:00 PM EDT - 3 months ago

Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC

2026-05-14T21:00:37.000Z - 3 months ago

Cardiff Oncology reports Q1 EPS (18c), consensus (12c)

2026-05-14T20:59:48.000Z - 3 months ago

Cardiff Oncology sees cash, equivalents funding operations into 1Q27

May 14, 2026, 4:10 PM EDT - 3 months ago

Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update

May 14, 2026, 7:00 AM EDT - 3 months ago

Cardiff Oncology Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 3 months ago

Cardiff Oncology Earnings release: Q1 2026

Apr 28, 2026, 4:01 PM EDT - 4 months ago

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 27, 2026, 7:00 AM EDT - 4 months ago

Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib's Promising Single-Agent Activity

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Cardiff Oncology Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Cardiff Oncology Proxy statement: Proxy filing

Apr 21, 2026, 10:00 AM EDT - 4 months ago

Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026

2026-04-17T20:14:54.000Z - 4 months ago

Cardiff Oncology to present preclinical data on onvansertib

Apr 17, 2026, 4:01 PM EDT - 4 months ago

Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting

2026-04-09T20:11:39.000Z - 4 months ago

Cardiff Oncology appoints Mani Mohindru CEO, Josh Muntner CFO

ACRS

Apr 9, 2026, 4:01 PM EDT - 4 months ago

Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth

Mar 25, 2026, 4:30 PM EDT - 5 months ago

Cardiff Oncology Transcript: KOL event

Mar 20, 2026, 7:00 AM EDT - 5 months ago

Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer

Mar 19, 2026, 7:00 AM EDT - 5 months ago

Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting

Feb 26, 2026, 4:01 PM EST - 6 months ago

Cardiff Oncology to Participate in Three Upcoming Investor Conferences

Feb 25, 2026, 1:20 PM EST - 6 months ago

Cardiff Oncology Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-02-25T12:21:13.000Z - 6 months ago

Cardiff Oncology price target lowered to $6 from $10 at Piper Sandler

Feb 24, 2026, 4:30 PM EST - 6 months ago

Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update

Feb 24, 2026, 7:00 AM EST - 6 months ago

Cardiff Oncology Earnings release: Q4 2025

Feb 24, 2026, 7:00 AM EST - 6 months ago

Cardiff Oncology Annual report: Q4 2025

Feb 19, 2026, 7:00 AM EST - 6 months ago

Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-01-28T11:15:48.000Z - 7 months ago

Cardiff Oncology selloff brings attractive entry point, says H.C. Wainwright

Jan 27, 2026, 8:30 AM EST - 7 months ago

Cardiff Oncology Transcript: Study result

Jan 27, 2026, 8:30 AM EST - 7 months ago

Cardiff Oncology Press release: Study result

Jan 27, 2026, 7:05 AM EST - 7 months ago

Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC

Jan 27, 2026, 7:00 AM EST - 7 months ago

Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

CTMX

Jan 7, 2026, 7:00 AM EST - 8 months ago

Cardiff Oncology Slides: Company presentation

Dec 11, 2025, 4:00 PM EST - 9 months ago

Cardiff Oncology Transcript: Sidoti's Year End Virtual Investor Conference

Dec 8, 2025, 4:05 PM EST - 9 months ago

Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025

Dec 8, 2025, 7:00 AM EST - 9 months ago

Cardiff Oncology to Present at Sidoti's Year-End Virtual Investor Conference

Dec 2, 2025, 9:30 AM EST - 9 months ago

Cardiff Oncology Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 7:00 AM EST - 9 months ago

Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 12, 2025, 9:20 AM EST - 10 months ago

Cardiff Oncology Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 9:30 AM EST - 10 months ago

Cardiff Oncology Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 6, 2025, 4:05 PM EST - 10 months ago

Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update

Nov 6, 2025, 4:00 PM EST - 10 months ago

Cardiff Oncology Earnings release: Q3 2025

Nov 6, 2025, 4:00 PM EST - 10 months ago

Cardiff Oncology Quarterly report: Q3 2025

Nov 4, 2025, 4:01 PM EST - 10 months ago

Cardiff Oncology to Participate in Two Upcoming Investor Conferences

Oct 9, 2025, 2:00 PM EDT - 11 months ago

Cardiff Oncology Transcript: Noble Capital Markets Emerging Growth Virtual Investor Conference

Sep 9, 2025, 10:30 AM EDT - 1 year ago

Cardiff Oncology Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 28, 2025, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Participate in Three Upcoming Investor Conferences

Jul 29, 2025, 4:30 PM EDT - 1 year ago

Cardiff Oncology Transcript: Study Update

Jul 29, 2025, 4:30 PM EDT - 1 year ago

Cardiff Oncology Press release: Study Update

Jul 29, 2025, 4:30 PM EDT - 1 year ago

Cardiff Oncology Slides: Study Update

Jul 29, 2025, 4:07 PM EDT - 1 year ago

Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)

Jul 29, 2025, 7:00 AM EDT - 1 year ago

Cardiff Oncology Earnings release: Q2 2025

Jul 29, 2025, 7:00 AM EDT - 1 year ago

Cardiff Oncology Quarterly report: Q2 2025

Jun 17, 2025, 4:39 PM EDT - 1 year ago

Cardiff Oncology Names Roger Sidhu as Medical Chief

Jun 17, 2025, 4:05 PM EDT - 1 year ago

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

Jun 2, 2025, 4:05 PM EDT - 1 year ago

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

May 8, 2025, 4:05 PM EDT - 1 year ago

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

May 8, 2025, 4:00 PM EDT - 1 year ago

Cardiff Oncology Earnings release: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Cardiff Oncology Quarterly report: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Cardiff Oncology Registration statement: Registration Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Cardiff Oncology Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Cardiff Oncology Proxy statement: Proxy Filing

Apr 23, 2025, 4:05 PM EDT - 1 year ago

Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients

Apr 15, 2025, 4:05 PM EDT - 1 year ago

Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer

Mar 5, 2025, 11:50 AM EST - 1 year ago

Cardiff Oncology Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 27, 2025, 4:30 PM EST - 1 year ago

Cardiff Oncology Earnings Call Transcript: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Cardiff Oncology Earnings release: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Cardiff Oncology Annual report: Q4 2024

Feb 27, 2025, 4:05 PM EST - 1 year ago

Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Feb 27, 2025, 7:00 AM EST - 1 year ago

Cardiff Oncology Registration statement: Registration Filing

Feb 24, 2025, 4:05 PM EST - 1 year ago

Cardiff Oncology to Present at Upcoming Investor Conferences

Feb 20, 2025, 4:05 PM EST - 1 year ago

Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

Dec 10, 2024, 8:00 AM EST - 1 year ago

Cardiff Oncology Transcript: Study Result

Dec 10, 2024, 8:00 AM EST - 1 year ago

Cardiff Oncology Press release: Study Result

Dec 10, 2024, 8:00 AM EST - 1 year ago

Cardiff Oncology Slides: Study Result

Dec 10, 2024, 7:20 AM EST - 1 year ago

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

Dec 10, 2024, 6:00 AM EST - 1 year ago

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

Nov 7, 2024, 4:00 PM EST - 1 year ago

Cardiff Oncology Quarterly report: Q3 2024

Nov 7, 2024, 4:00 PM EST - 1 year ago

Cardiff Oncology Earnings release: Q3 2024

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC

Aug 8, 2024, 4:30 PM EDT - 2 years ago

Cardiff Oncology Earnings Call Transcript: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

Cardiff Oncology Quarterly report: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

Cardiff Oncology Earnings release: Q2 2024

Jun 17, 2024, 8:00 AM EDT - 2 years ago

Cardiff Oncology Proxy statement: Proxy Filing

Jun 5, 2024, 8:30 AM EDT - 2 years ago

Cardiff Oncology Transcript: Jefferies 2024 Global Healthcare Conference

Jun 3, 2024, 8:00 AM EDT - 2 years ago

Cardiff Oncology Proxy statement: Proxy Filing

May 29, 2024, 4:05 PM EDT - 2 years ago

Cardiff Oncology to Present at the Jefferies Healthcare Conference

May 29, 2024, 1:30 PM EDT - 2 years ago

Cardiff Oncology Transcript: TD Cowen 5th Annual Oncology Innovation Virtual Summit

May 20, 2024, 2:30 PM EDT - 2 years ago

Cardiff Oncology Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 13, 2024, 4:05 PM EDT - 2 years ago

Cardiff Oncology to Present at Upcoming Investor Conferences in May

May 2, 2024, 4:30 PM EDT - 2 years ago

Cardiff Oncology Earnings Call Transcript: Q1 2024

May 2, 2024, 4:30 PM EDT - 2 years ago

Cardiff Oncology Quarterly report: Q1 2024

May 2, 2024, 4:30 PM EDT - 2 years ago

Cardiff Oncology Earnings release: Q1 2024

May 2, 2024, 4:05 PM EDT - 2 years ago

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update

Apr 25, 2024, 4:05 PM EDT - 2 years ago

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Cardiff Oncology Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Cardiff Oncology Proxy statement: Proxy Filing

Apr 8, 2024, 4:05 PM EDT - 2 years ago

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

Mar 6, 2024, 4:05 PM EST - 2 years ago

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024

Mar 4, 2024, 1:30 PM EST - 2 years ago

Cardiff Oncology Transcript: TD Cowen 44th Annual Health Care Conference 2024

Feb 29, 2024, 4:30 PM EST - 2 years ago

Cardiff Oncology Earnings Call Transcript: Q4 2023

Feb 29, 2024, 4:30 PM EST - 2 years ago

Cardiff Oncology Earnings release: Q4 2023

Feb 29, 2024, 4:30 PM EST - 2 years ago

Cardiff Oncology Annual report: Q4 2023

Feb 29, 2024, 4:30 PM EST - 2 years ago

Cardiff Oncology Slides: Q4 2023

Feb 29, 2024, 4:07 PM EST - 2 years ago

Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

Feb 29, 2024, 4:06 PM EST - 2 years ago

Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC

Feb 29, 2024, 4:05 PM EST - 2 years ago

Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)

Feb 26, 2024, 8:00 AM EST - 2 years ago

Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference

Feb 22, 2024, 8:00 AM EST - 2 years ago

Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update

Jan 17, 2024, 10:30 AM EST - 2 years ago

Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research

Nov 29, 2023, 10:00 AM EST - 2 years ago

Cardiff Oncology Transcript: Piper Sandler 35th Annual Healthcare Conference

Nov 20, 2023, 4:05 PM EST - 2 years ago

Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference

Swing22 Aug. 24 at 3:17 PM

$CRDF great time to sell this loser stock and move on with your life

0 · Reply

spaarrow1 Aug. 24 at 3:16 PM

$CRDF Im waiting for BO. But Will not happend.

0 · Reply

Blakeruss1 Aug. 24 at 3:13 PM

$CRDF meteoric rise this morning!! Flat rest of day until buyout announced later

0 · Reply

spaarrow1 Aug. 24 at 3:10 PM

$CRDF This a pump and dump. Tomorrow 0.9

0 · Reply

jrh34 Aug. 24 at 2:56 PM

1 · Reply

Blakeruss1 Aug. 24 at 2:45 PM

$CRDF I heard buyout between 55-60

2 · Reply

DBOCK Aug. 24 at 2:43 PM

$CRDF Please announce a settlement so we can move forward with this behind us.

0 · Reply

JanetBSmellin Aug. 24 at 2:31 PM

$CRDF Buyout $5.00😛

2 · Reply

jrh34 Aug. 24 at 2:30 PM

0 · Reply

OneSmartBull Aug. 24 at 2:26 PM

$CRDF

0 · Reply

TradeMark79 Aug. 24 at 2:22 PM

$CRDF nice🤙🏼

1 · Reply

Setura Aug. 24 at 2:13 PM

$CRDF close to 16 percent nice! :)

0 · Reply

Lord_Andrew_London Aug. 24 at 1:57 PM

$CRDF I agree with Uncle Tom. I am less ambitious but Buyout Is the only reasonable outcome for this Company. Strong buy.

1 · Reply

Blakeruss1 Aug. 24 at 1:53 PM

$CRDF volume is breathtaking. A closer above .97 very bullish

0 · Reply

Uncle_Tom Aug. 24 at 1:49 PM

$CRDF

1 · Reply

E_Dantes87 Aug. 24 at 1:49 PM

$CRDF

0 · Reply

rag2riches Aug. 24 at 1:47 PM

$CRDF lawyer friends and family on both ends leaking settlement. Lawyers double dipping with legal fees and crdf gains, smh. Bandits

2 · Reply

Setura Aug. 24 at 1:39 PM

$CRDF 12 percent plus nice

0 · Reply

DD_investments Aug. 24 at 1:38 PM

$CRDF something get leaked ahead of today’s meeting?

1 · Reply

Blakeruss1 Aug. 24 at 1:35 PM

$CRDF billions

0 · Reply

Blakeruss1 Aug. 24 at 1:21 PM

$CRDF pi granted

0 · Reply

jrh34 Aug. 24 at 1:02 PM

$CRDF thoughts on where this lands with a settlement? That $2.80-$3.20 rang was pretty sticky for a long time. Seems like a reasonable spot for this to be while P3 happens. Obviously much higher if we had a settlement then buyout, but that scenario seems unlikely right now.

1 · Reply

Market Cap	68.47M
Revenue (ttm)	590,000.00
Net Income (ttm)	-45.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-7,771.19%
Debt to Equity Ratio	0.00

Volume	653,400
Avg Vol	1,351,518
Day's Range	N/A - N/A
Shares Out	77.80M
Stochastic %K	5%
Beta	1.49
Analysts	Sell
Price Target	$5.45